Document is current

Article History

Received: 16 September 2024

Accepted: 9 January 2025

First Online: 14 March 2025

Declarations

:

: The protocol for the experimental animal studies was approved by the German regional committee for animal care and use, which is equivalent to the US IACUC, and by governmental authorities (Regierung von Unterfranken, approval numbers 55.2.2-2532-2-1127 for ischemia/reperfusion and 54-2532.1-14/12 for 5/6-nephrectomy). The studies were conducted in strict accordance with the German Animal Welfare Act and using the ARRIVE reporting guidelines. The use of remnant kidney biopsy material has been approved by the Ethics Committee of the Friedrich-Alexander University of Erlangen-Nuremberg, waiving the need for retrospective consent for the use of archived excess material (Ref. No. 22-150-D).

: Not applicable.

: KA, MBH and CD were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) within the Project C2 of the TRR374 (509149993). KA has received honoraria for lectures from Novartis, Alexion, Vifor, Stadapharm, Otsuka, Böhringer and participated in Data Safety Monitoring for Novartis and holds stocks for Roche, Pfizer and Merck. MBH received honoraria for lectures from Sanofi, Pfizer, Springer, Thieme and the Volhard-Fahr Course of Nephropathology. JS participated in patents from the University Charitè Berlin (1/3; Inhibition of vascular calcification by Uromodulin), in Data Safety Advisory Board German lab guidelines (AWMF) on early diagnosis of AKI and the Board of the German Soc Nephrol “Prevention of kidney diseases”. All the other authors declared no competing interests.